ABSTRACT
In 2023, the improvement of our therapeutic management has largely taken shape. The aim of our article is to highlight the major advances that will change our practices. These are not only in the field of treatment, but also in the improvement of supportive care. Here, we present these new developments organ by organ, cancer by cancer. You can read everything or concentrate on the cancers that are your areas of expertise. But this exhaustiveness should be representative of our current state of progress.
Subject(s)
Neoplasms , Humans , Neoplasms/therapy , Medical OncologyABSTRACT
The Cancer Bulletin continues its tradition. At the beginning of 2023, the members of the editorial committee would like to share with you their analyses of the highlights of 2022. The objective remains to highlight what will change our practices and lead to different diagnostic or therapeutic options. Our synthesis will therefore focus on published data. They have been analyzed and placed in the more general context of the management of each type of cancer to deduce the practical consequences for our patients. This synthesis exercise will concern almost all tumor pathologies, most often on the therapeutic level, and will, however, exclude the evolution of techniques, whether they are diagnostic or used for the follow-up of our patients. The final objective is to allow you to have a thoughtful, didactic and practical reading. Our goal is to provide our readers with the rational bases that can lead to a different approach for treatments in 2023.
Subject(s)
Medical Oncology , Neoplasms , Humans , Neoplasms/diagnosis , Neoplasms/therapyABSTRACT
Once again this year, the Editorial Board presents here a summary of the most important advances in treatment and patient care in oncology over the past year. Some of the most important results in breast and gynecological cancers (endometrium and cervix), lung, brain, urologic and digestive cancers. Are also presented progresses in hematological malignancies, pediatric oncology, and of course supportive care essential for our patients.
Subject(s)
Medical Oncology/trends , Neoplasms/therapy , Antineoplastic Agents/therapeutic use , Brain Neoplasms/therapy , Breast Neoplasms/therapy , Clinical Trials as Topic , Endometrial Neoplasms/therapy , Female , Gastrointestinal Neoplasms/therapy , Hematologic Neoplasms/therapy , Humans , Immunotherapy , Lung Neoplasms/therapy , Male , Prostatic Neoplasms/therapy , Rhabdomyosarcoma/therapy , Urologic Neoplasms/therapy , Uterine Cervical Neoplasms/therapyABSTRACT
The editorial committee of the Bulletin du Cancer is proud to comply with his annual analysis of some of the worldwide updates in oncology that emerge in 2020. We know that all new breakthroughs will not be addressed and apologise for not being comprehensive, but we hope that the topics deciphered herein will bring the reader interesting information in his daily practice in gyneco-oncology, uro-oncology, neuro-oncology, digestive oncology, pneumo-oncology, hemato-oncology, pediatric oncology, or in palliative care.
Subject(s)
Medical Oncology , Neoplasms/therapy , Antineoplastic Agents/therapeutic use , Brain Neoplasms/therapy , Digestive System Neoplasms/therapy , Female , Genital Neoplasms, Female/therapy , Glioblastoma/therapy , Hematologic Neoplasms/therapy , Humans , Lung Neoplasms/therapy , Male , Neoplasms, Unknown Primary/therapy , Prostatic Neoplasms, Castration-Resistant/genetics , Prostatic Neoplasms, Castration-Resistant/therapy , Urologic Neoplasms/therapySubject(s)
Medical Oncology , Periodicals as Topic , Societies, Medical , Congresses as Topic/organization & administration , Diffusion of Innovation , Editorial Policies , France , Humans , Medical Oncology/organization & administration , Medical Oncology/trends , Neoplasms/drug therapy , Therapies, InvestigationalABSTRACT
The editorial board of Bulletin du Cancer presents some hot topics published or presented in major oncology meetings in 2018. This selection is related to pediatric oncology and to solid and hemato-malignancies in adults, with immunotherapy approaches (checkpoints or CAR-T) as one of the major breakthroughs. Putative impacts on daily practices are discussed, in order to detail what will really change our practice.
Subject(s)
Medical Oncology/trends , Neoplasms/therapy , Adult , Child , Clinical Trials as Topic , Hematologic Neoplasms/therapy , Humans , Immunotherapy/trendsABSTRACT
Actuality was dense in 2017 for oncology and hematology. The editorial board of the Bulletin du Cancer proposes a selection of key data distinguishing four trends: precision medicine, immunotherapy, focus on early stages and global management of metastatic disease. A summary of results which have been published or presented in congresses is proposed and the impact on daily practices is discussed.
